Clinical Trial Update: Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating decitabine plus carboplatin versus physician's choice chemotherapy for recurrent, platinum-resistant ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Decitabine (Decitabine)

Snippet

Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Conditions: Recurrent, Platinum-resistant Ovarian Cancer | Phase 2 | Status: UNKNOWN